- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02631109
L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100050
- Recruiting
- Beijing Friendship Hospital, Capital Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients were older than 14 years of age
- Diagnosed as EBV-Hemophagocytic Lymphohistiocytosis (HLH)
- Patients did not achieve at lease partial response after initial treatment including HLH-94 or DEP no less than 2 weeks
- Informed consent
Exclusion Criteria:
- Heart function above grade II (NYHA)
- Accumulated dose of doxorubicin above 300mg/m2 or epirubicin above 450mg/m2
- Pregnancy or lactating Women
- Allergic to Pegaspargase, doxorubicin or etoposide
- Active bleeding of the internal organs
- uncontrollable infection
- history of acute and chronic pancreatitis
- Participate in other clinical research at the same time
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: L-DEP
Pegaspargase 2000U/m2 day5; doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered once on the first day of every week; methylprednisolone 15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
|
2000U/m2 day5
25mg/m2 day1
100 mg/m2 was administered once on the first day of every week
15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of treatment response
Time Frame: Change from before and 2,4,6 and 8 weeks after initiating L-DEP salvage therapy
|
A complete response was defined as normalization of all of the quantifiable symptoms and laboratory markers of HLH, including levels of sCD25, ferritin, and triglyceride; hemoglobin; neutrophil counts; platelet counts; and alanine aminotransferase (ALT). A partial response was defined as at least a 25% improvement in 2 or more quantifiable symptoms and laboratory markers as follows: sCD25 response was>1.5-fold decreased; ferritin and triglyceride decreased at least 25%; for patients with an initial neutrophil count of<0.5 ×109/L, a response was defined as an increase by at least 100% to>0.5× 109/L; for patients with a neutrophil count of 0.5 to 2.0 × 109/L, an increase by at least 100% to >2.0 × 109/L was considered a response; and for patients with ALT >400 U/L, response was defined as an ALT decrease of at least 50%. |
Change from before and 2,4,6 and 8 weeks after initiating L-DEP salvage therapy
|
Change of Epstein-Barr virus(EBV)-DNA
Time Frame: Change from before and 2, 4, 6 and 8 weeks after initiating L-DEP salvage therapy
|
Change from before and 2, 4, 6 and 8 weeks after initiating L-DEP salvage therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival
Time Frame: from the time patients received L-DEP salvage therapy up to 24 months or November 2019
|
from the time patients received L-DEP salvage therapy up to 24 months or November 2019
|
|
Adverse events that are related to treatment
Time Frame: through study completion, an average of 2 years
|
Adverse events including pancreatitis, liver function damage, myelosuppression, infection, bleeding and so on.
|
through study completion, an average of 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: zhao wang, M.D., Beijing Friendship Hospital
Publications and helpful links
General Publications
- Wang Y, Huang W, Hu L, Cen X, Li L, Wang J, Shen J, Wei N, Wang Z. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Blood. 2015 Nov 5;126(19):2186-92. doi: 10.1182/blood-2015-05-644914. Epub 2015 Aug 19.
- Wang J, Wang Y, Wu L, Zhang J, Lai W, Wang Z. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Hematol Oncol. 2016 Sep 9;9(1):84. doi: 10.1186/s13045-016-0317-7.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Virus Diseases
- Infections
- Lymphatic Diseases
- DNA Virus Infections
- Tumor Virus Infections
- Herpesviridae Infections
- Histiocytosis, Non-Langerhans-Cell
- Histiocytosis
- Epstein-Barr Virus Infections
- Lymphohistiocytosis, Hemophagocytic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Neuroprotective Agents
- Protective Agents
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Methylprednisolone
- Etoposide
- Doxorubicin
- Pegaspargase
Other Study ID Numbers
- L-DEP-EBV-HLH
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemophagocytic Lymphohistiocytosis
-
The First Affiliated Hospital with Nanjing Medical...Unknown
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Children's Hospital Medical Center, CincinnatiBaylor College of Medicine; Sobi, Inc.RecruitingHemophagocytic LymphohistiocytosesUnited States
-
Swedish Orphan BiovitrumLight Chain Bioscience - Novimmune SATerminatedHemophagocytic LymphohistiocytosesUnited States
-
Swedish Orphan BiovitrumHarvard Medical School (HMS and HSDM); Brigham and Women's HospitalCompletedHemophagocytic LymphohistiocytosesUnited States
-
University of California, San FranciscoIncyte CorporationNot yet recruitingRuxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)Hemophagocytic LymphohistiocytosesUnited States
-
Beijing Friendship HospitalNot yet recruitingEBV | Hemophagocytic Lymphohistiocytoses | MetabonomicsChina
-
Beijing Friendship HospitalRecruitingHemophagocytic LymphohistiocytosisChina
-
St. Jude Children's Research HospitalIncyte Corporation; North American Consortium for Histiocytosis; Cures Within...RecruitingHemophagocytic LymphohistiocytosisUnited States
-
Swedish Orphan BiovitrumSeventh Framework ProgrammeCompletedHemophagocytic LymphohistiocytosisUnited States, France, Italy, Spain, United Kingdom
Clinical Trials on Pegaspargase
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruiting
-
Assistance Publique - Hôpitaux de ParisShireRecruitingAcute Lymphoblastic LeukemiaFrance
-
Fudan UniversityRecruitingNatural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeChina
-
Rong TaoCompletedSocial Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL PatientsExtranodal NK-T-Cell Lymphoma, Nasal TypeChina
-
Sun Yat-sen UniversityRecruitingNK/T Cell Lymphoma NosChina
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI); ShireActive, not recruitingAcute Lymphoblastic Leukemia | Lymphoblastic LymphomaUnited States, Canada, Puerto Rico
-
Ruijin HospitalNot yet recruiting
-
medac GmbHTerminatedAcute Lymphoblastic LeukaemiaGermany
-
Sun Yat-sen UniversityTerminatedTreatment RefusalChina
-
Nordic Society for Pediatric Hematology and OncologyDanish Child Cancer Foundation; Medac, Hamburg, GermanyUnknownAcute Lymphoblastic LeukemiaDenmark